China Wants to Invent 1 in 4 of the World's New Drugs. By 2030.

The plan calls for 20% annual growth in China's innovative-drug sector through 2030. It wants at least five Chinese-developed drugs generating more than $1 billion each in global annual sales. It expects listed pharma companies to spend over 10% of revenue on R&D, a level that would rival the research intensity of major Western drugmakers.

On the industrial scale side, the targets include 50 pharma companies with revenue above 10 billion yuan, 20 pharma industrial parks each generating over 100 billion yuan, and total pharmaceutical industry revenue surpassing 3.5 trillion yuan. There's even a goal for 200+ innovative medical devices approved by the end of the decade.

This isn't a wish list scribbled on a napkin. It's a coordinated national strategy backed by ten government departments.

A Decade of Groundwork Made This Possible

China didn't wake up one morning and decide to become an innovation powerhouse. The foundation was laid over a decade of regulatory reform that quietly transformed how drugs get developed and approved in the country.

The turning point came in 2015, when the State Council overhauled drug review and approval, slashing a massive backlog and speeding up the process. That same year, Made in China 2025 elevated biomedicine to a strategic national priority. In 2018, the NMPA replaced the older CFDA, modernizing the regulator. A year later, a revised Drug Administration Law codified faster, clearer approval pathways.

By 2020, China had added priority review, conditional approval, and breakthrough therapy designations that mirror the FDA's expedited programs. It also shortened clinical trial application review to 60 working days, aligning more closely with international standards.

The result: domestic companies now drive the majority of China's innovative-drug approvals. From 2022 to 2024, 79 of the 96 Class 1 approvals came from domestic firms, compared to just 17 from multinationals. And oncology dominates the pipeline, accounting for 46% of all Class 1 approvals in that period.

What This Means for Global Pharma (and Your Portfolio)

If China hits even half of these targets, the ripple effects will reshape global biopharma in three important ways.

First, the licensing market gets more interesting. Chinese innovative-drug licensing deals have been growing rapidly, with Western pharma already depending heavily on Chinese assets, particularly in hot areas like antibody-drug conjugates and immuno-oncology. More first-in-class programs from China means more deal flow, but also more competition for the best assets.

Second, bargaining power shifts. Top Chinese innovators with genuinely differentiated pipelines could start demanding better terms: co-development agreements, profit splits, even co-commercialization rights instead of simple license-out deals. The days of Western companies scooping up Chinese assets on the cheap may be numbered.

Third, regulatory competition intensifies. If the NMPA becomes a credible first-approval destination for novel drugs (as of mid-2026, six global first-in-class drugs were first approved by the NMPA before the FDA), it changes the calculus for where companies launch first. That has implications for everything from clinical trial design to pricing strategy.

The Catch

Ambitious national targets and actual outcomes don't always align, especially in drug development. Biology doesn't care about five-year plans. Discovering genuinely novel mechanisms of action isn't something you can manufacture on a government timeline the way you build highways or solar panels.

There's also a definition problem. Different organizations count "first-in-class" differently. One study found China had 15 first-in-class drugs from 2019 to 2023, while the NMPA itself reported 48 first-in-class innovative drugs in 2024 alone. The discrepancy comes down to methodology: what counts as truly novel versus a new-ish twist on an existing approach. How China defines the 25% target will matter enormously.

And then there's geopolitics. Cross-border data sharing, export controls on biotech tools, and political tensions around technology transfer could all complicate China's push to globalize its drug innovations. A brilliant molecule doesn't help much if it can't get approved in the markets where the money is.

The Bottom Line

China is no longer content to be pharma's factory floor or its licensing catalog. The 25% target is a declaration of intent: Beijing wants Chinese scientists inventing the drugs that change medicine, not just manufacturing the ones invented elsewhere.

Whether the country actually gets there by 2030 is an open question. But the trajectory, the regulatory infrastructure, and the sheer scale of investment all point in the same direction. Global pharma's competitive landscape is being redrawn, and the biggest player you might not have been watching closely enough is the one making the boldest bets.

Sarepta's Worst Week Just Rewrote the Gene Therapy Playbook

Sarepta slapped a black box warning on its Duchenne gene therapy Elevidys and cut 36% of its workforce in one brutal announcement. The fallout raises hard questions about the commercial future of accelerated-approval gene therapies in rare disease.